RxDoctor Payments DataLook up a doctor →

Howard Safran, MD

Hematology & Oncology · Providence, RINPI 1982616744

Payments from drug & device makers

$3,966,188in general payments, 2019–2025

Across 266 payments — averaging $14,910 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$1.3M
  • Pfizer$949K
  • Regeneron$572K
  • Chugai Pharmaceutical Co., Ltd.$562K
  • Seagen Inc.$345K
  • Genentech, Inc.$100K
  • plus $145K from 7 others
$1,492in research payments, 2019–2025

Across 4 payments — averaging $372.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$1K
  • Regeneron$222

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,966,188 in reported general payments places this provider in the 95th percentile of 68 hematology & oncology providers in Rhode Island.

See all hematology & oncology providers in Rhode Island

Medicare billing

Part B allowed, 2024
$82,996
Medicare patients
219
Services billed
790

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →